【中国新闻网】助力肺癌早期诊断 中国研发全球首个肺结节辅助诊断试剂盒获批上市

Core Viewpoint - The research team from the Chinese Academy of Sciences Hangzhou Institute of Medicine has developed a groundbreaking lung cancer-related antibody detection kit, which has received regulatory approval as the world's first auxiliary diagnostic kit for distinguishing the malignancy of lung nodules detected by CT scans, potentially improving early lung cancer diagnosis rates significantly [2][3]. Group 1: Product Development and Approval - The developed kit consists of 13 optimal combinations of lung cancer-related antibodies and has been officially registered as a Class III medical device by the National Medical Products Administration [2]. - The kit addresses the challenge of distinguishing between benign and malignant small lung nodules, which is crucial for early lung cancer diagnosis and reducing mortality rates [3]. Group 2: Technical Innovations - The research team utilized a large cancer tissue library and high-throughput screening technologies to identify over 400 key proteins related to early lung cancer, ultimately selecting 13 diagnostic markers, eight of which are newly discovered [3]. - The team overcame production challenges by innovating in protein labeling design and optimizing buffer formulations, resulting in a shelf life of 12 months for the kit under refrigerated conditions [4]. Group 3: Clinical Validation and Application - Multi-center clinical trials involving 1,463 lung nodule patients demonstrated that the kit has a sensitivity of over 65% for early lung cancer detection, significantly outperforming traditional tumor markers [4]. - The kit requires only 2 milliliters of blood for testing, minimizing the risks associated with invasive procedures and improving patient compliance, especially among the elderly or those with underlying health conditions [4]. Group 4: Future Implications - This technology represents a milestone in early lung cancer diagnosis, shifting the focus from morphological observation to molecular analysis, and is expected to enhance screening coverage in high-risk populations [5]. - The breakthrough supports the "Healthy China 2030" cancer early screening strategy, aiming to alleviate public anxiety regarding lung nodules and advance lung cancer prevention and treatment [5].